These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study. Yu S; Sun Z; Zong L; Yan J; Yu M; Chen J; Lu Z J Gynecol Oncol; 2022 May; 33(3):e38. PubMed ID: 35320887 [TBL] [Abstract][Full Text] [Related]
12. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy. Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914 [TBL] [Abstract][Full Text] [Related]
13. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Krämer P; Talhouk A; Brett MA; Chiu DS; Cairns ES; Scheunhage DA; Hammond RFL; Farnell D; Nazeran TM; Grube M; Xia Z; Senz J; Leung S; Feil L; Pasternak J; Dixon K; Hartkopf A; Krämer B; Brucker S; Heitz F; du Bois A; Harter P; Kommoss FKF; Sinn HP; Heublein S; Kommoss F; Vollert HW; Manchanda R; de Kroon CD; Nijman HW; de Bruyn M; Thompson EF; Bashashati A; McAlpine JN; Singh N; Tinker AV; Staebler A; Bosse T; Kommoss S; Köbel M; Anglesio MS Clin Cancer Res; 2020 Oct; 26(20):5400-5410. PubMed ID: 32737030 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer. Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529 [TBL] [Abstract][Full Text] [Related]
15. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603 [TBL] [Abstract][Full Text] [Related]
16. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting. Casey L; Singh N Int J Gynecol Pathol; 2021 Jan; 40(1):5-16. PubMed ID: 33290350 [TBL] [Abstract][Full Text] [Related]
17. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population. Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742 [TBL] [Abstract][Full Text] [Related]
18. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219 [TBL] [Abstract][Full Text] [Related]
19. ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma. Kitazono I; Kobayashi Y; Akahane T; Yamaguchi T; Yanazume S; Nohara S; Sakamoto I; Tabata K; Tasaki T; Kobayashi H; Tanimoto A Pathol Res Pract; 2022 Feb; 230():153743. PubMed ID: 34954471 [TBL] [Abstract][Full Text] [Related]
20. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification. Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]